The breast biopsy needle market is a technology‑intensive and steadily growing niche segment within the medical device industry. Its growth directly benefits from the global popularization of breast cancer screening, deeper adoption of minimally invasive diagnosis and treatment concepts, and surging demand for precision medicine. The current market is characterized by dominance of international giants, rise of domestic enterprises, and accelerated technological iteration, with the competitive landscape reshaping dynamically.

Global Market: Dominated by Industry Giants, Technology as the Core Competitiveness

The global breast biopsy market is led by a small number of multinational medical device giants that own core technologies and comprehensive solution portfolios. They typically provide not only biopsy needles but also supporting biopsy guns, vacuum‑assisted systems and even image‑guided devices, forming strong systematic barriers.

Hologic: With its Mammotome® series vacuum‑assisted biopsy systems, Hologic has long held a leading position in this field. Covering stereotactic, ultrasound and MRI‑guided platforms, the Mammotome series has become standard equipment at numerous breast centers worldwide, thanks to its reliable performance and abundant clinical data.

BD (Becton, Dickinson and Company): Through the acquisition of C.R. Bard, BD obtained breast biopsy product lines including the Vacora® vacuum‑assisted biopsy system. With profound expertise in injection and puncture devices, its biopsy products excel in human‑centric design and stability.

Medtronic: As one of the world's largest medical device companies, Medtronic has extensive layouts in minimally invasive surgery. Though its breast biopsy product line is relatively low‑profile, it still maintains a global market presence backed by robust distribution channels and brand influence.

Stryker, along with biopsy‑focused enterprises such as Galini SRL and GMT Medical, also hold market shares in specific regions or product categories.

The competitive edges of these international giants lie in three aspects:

Solid patent barriers: A large number of patents covering core segments including rotary cutting tip design, vacuum control and specimen management.

Comprehensive clinical evidence chains: Decades‑long accumulated clinical research data supporting product efficacy and safety.

Extensive global marketing and service networks.

Chinese Market: Ongoing Import Substitution with Rising Domestic Players

China's breast biopsy needle market has expanded rapidly alongside the advancement of breast cancer screening programs and improved medical standards. According to a report by Hengce Consulting, major market players in China include both the above‑mentioned international brands and a group of competitive local enterprises. The market is shifting from absolute dominance by imported products to a dual pattern of imported and domestic alternatives.

International brands still dominate the high‑end market: VABB systems from Hologic, BD and other brands boast high installation rates and user stickiness in high‑level medical institutions such as tertiary hospitals. Their products deliver stable performance yet come with high prices, plus continuous purchase costs for disposable rotary cutting needle consumables.

Domestic enterprises achieve key technological breakthroughs: In recent years, a number of Chinese medical device firms have successfully broken the technological monopoly of vacuum‑assisted rotary cutting biopsy needles through independent R&D, and obtained Class III medical device registration certificates issued by the National Medical Products Administration (NMPA). This marks that domestic products have met market access standards in terms of safety and efficacy.

Chongqing Xishan Technology Co., Ltd.：Its Disposable Breast Rotary Cutting Biopsy Needle (NMPA Registration No. 20233011665) has been approved for marketing, emerging as a pioneer domestic product.

Bons Medical Technology Co., Ltd.：Its Disposable Breast Rotary Cutting Biopsy Puncture Needle (NMPA Registration No. 20233011945) has also entered the market, offering another domestic alternative.

Xiamen Runding Minimally Invasive Precision Technology Co., Ltd.：As an upstream precision component manufacturer, it provides OEM/ODM services for multiple biopsy device enterprises. Its biopsy needle tips adopt special steel materials and integrated design, reflecting the manufacturing capacity of China's domestic supply chain.

Deepening industrial chain division of labor: Besides complete‑product manufacturers, specialized OEM/ODM producers such as ZorayPT have emerged, delivering one‑stop biopsy needle manufacturing solutions from design to production for brand owners, highlighting the trend of specialized division of labor in the industrial chain.

Competitive Focus and Future Trends

Current market competition has expanded beyond mere product performance to cost‑effectiveness of overall solutions, clinician operation training, and after‑sales technical support. Medical insurance cost‑control policies such as Group Purchasing Organization (GPO) have created a window for cost‑effective domestic products to accelerate import substitution.

In the future, the evolution of the market landscape will depend on three factors:

Clinical recognition and large‑scale application data accumulation of domestic products.

Innovation speed in next‑generation technologies including finer‑gauge needles and intelligence (e.g., integration with AI image recognition).

Enterprises' capacity to transform from single‑product suppliers to integrated solution providers featuring "devices + consumables + services".

It is foreseeable that against the backdrop of Made in China 2025 and domestic substitution of high‑end medical devices, domestic breast biopsy needle manufacturers represented by Xishan Technology and Bons Medical are embracing historic development opportunities.